Variability in the clinical management of fatty acid oxidation disorders: results of a survey of Canadian metabolic physicians
- 1 June 2011
- journal article
- research article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 35 (1) , 115-123
Abstract
Introduction: There is little robust empirical evidence on which to base treatment recommendations for fatty acid oxidation disorders. While consensus guidelines are important, understanding areas where there is a lack of consensus is also critical to inform priorities for future evaluative research.Methods: We surveyed Canadian metabolic physicians on the treatment of medium‐chain acyl‐CoA dehydrogenase (MCAD) deficiency, very long‐chain acyl‐CoA dehydrogenase (VLCAD) deficiency, long‐chain 3‐hydroxyacyl‐CoA dehydrogenase (LCHAD) deficiency, and mitochondrial trifunctional protein (MTP) deficiency. We ascertained physicians’ opinions on the use of different interventions for the long‐term management of patients as well as for the management of acute illness, focusing on identifying interventions characterized by high variability in opinions. We also investigated factors influencing treatment decisions.Results: We received 18 responses (response rate 45%). Participants focused on avoidance of fasting and increased meal frequency as interventions for the management of MCAD deficiency. For the long‐chain disorders, avoidance of fasting remained the most consistently endorsed intervention, with additional highly endorsed treatments differing for VLCAD versus LCHAD/MTP deficiency. L‐carnitine supplementation and restriction of dietary fat were characterized by high variability in physicians’ opinions, as were several interventions specific to long‐chain disorders. Social factors and patient characteristics were important influences on treatment decisions.Conclusions: Based on our findings we suggest that high priority treatments for rigorous effectiveness studies could include L‐carnitine supplementation (MCAD and LCHAD/MTP deficiencies), restriction of dietary fat, and, for the long‐chain disorders, feeding practices for breastfed infants and the use of various supplements (essential fatty acids, carbohydrates, cornstarch, multivitamins).Keywords
Funding Information
- University of Ottawa
This publication has 25 references indexed in Scilit:
- Clinical trials: Curing a critical deficiency in metabolic medicineMolecular Genetics and Metabolism, 2010
- Lack of genotype–phenotype correlations and outcome in MCAD deficiency diagnosed by newborn screening in New York StateMolecular Genetics and Metabolism, 2010
- Management and outcome in 75 individuals with long‐chain fatty acid oxidation defects: results from a workshopJournal of Inherited Metabolic Disease, 2009
- A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiencyMolecular Genetics and Metabolism, 2009
- Clinical research for rare disease: Opportunities, challenges, and solutionsMolecular Genetics and Metabolism, 2009
- Effects of higher dietary protein intake on energy balance and metabolic control in children with long-chain 3-hydroxy acyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiencyMolecular Genetics and Metabolism, 2006
- Metabolic control during exercise with and without medium-chain triglycerides (MCT) in children with long-chain 3-hydroxy acyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiencyMolecular Genetics and Metabolism, 2006
- Komrower lecture: Treatment of inborn errors of metabolism: A reviewJournal of Inherited Metabolic Disease, 2005
- Potential of fibrates in the treatment of fatty acid oxidation disorders: Revival of classical drugs?Journal of Inherited Metabolic Disease, 2005
- Evidence based medicine in inborn errors of metabolism: Is there any and how to find itAmerican Journal of Medical Genetics Part A, 2005